Literature DB >> 25862872

Scoring system based on tumor markers and Child-Pugh classification for HCC patients who underwent liver resection.

Shigeki Nakagawa1, Hiromitsu Hayashi1, Hidetoshi Nitta1, Hirohisa Okabe1, Keita Sakamoto1, Takaaki Higashi1, Hideyuki Kuroki1, Katsunori Imai1, Daisuke Hashimoto1, Yasuo Sakamoto2, Akira Chikamoto1, Toru Beppu2, Hideo Baba3.   

Abstract

BACKGROUND: The long-term prognosis of hepatocellular carcinoma (HCC) patients after hepatic resection (HR) remains poor because of limited liver function and frequent recurrences. We created a prognostic system of HCC based on tumor markers and Child-Pugh classification. PATIENTS AND METHODS: This study investigated 427 HCC patients and three tumor markers (alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ -carboxyprothrombin (DCP)) in relation to Child-Pugh classification by the stepwise Cox regression model for establishing a tumor marker staging (TMS).
RESULTS: The TMS shows four levels (0/1/2/3) with 5-year recurrence rate of each stage of 76.7, 72.3, 80.9 and 100%, respectively, and 5-year overall survival of 77.0, 68.7, 52.1 and 28.9%, respectively. This TMS appears to be a better model to predict the recurrence and survival of HCC patients after hepatectomy than only the number of positive tumor markers.
CONCLUSION: TMS is a useful staging system to evaluate biological status and background liver function. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3); alpha-fetoprotein (AFP); des-γ-carboxyprothrombin (DCP); tumor marker

Mesh:

Substances:

Year:  2015        PMID: 25862872

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

2.  Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma.

Authors:  Biao Wu; Yumeng Wu; Xianlin Guo; Yifei Liu; Yanping Yue; Wenjing Zhao; Jibin Liu; Xuming Wu; Aiguo Shen; Suqing Zhang
Journal:  Med Sci Monit       Date:  2022-06-21

Review 3.  The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma.

Authors:  Toru Beppu; Shigeki Nakagawa; Hidetoshi Nitta; Hirohisa Okabe; Takayoshi Kaida; Katsunori Imai; Hiromitsu Hayashi; Yuki Koga; Kunitaka Kuramoto; Daisuke Hashimoto; Yo-Ichi Yamashita; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  J Clin Transl Hepatol       Date:  2017-05-10

4.  Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.

Authors:  Chunli Kong; Zhongwei Zhao; Weiyue Chen; Xiuling Lv; Gaofeng Shu; Miaoqing Ye; Jingjing Song; Xihui Ying; Qiaoyou Weng; Wei Weng; Shiji Fang; Minjiang Chen; Jianfei Tu; Jiansong Ji
Journal:  Eur Radiol       Date:  2021-04-16       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.